92 related articles for article (PubMed ID: 18336911)
1. Transcriptional silencing of RFXAP in MHC class II-deficiency.
van Eggermond MC; Tezcan I; Heemskerk MH; van den Elsen PJ
Mol Immunol; 2008 May; 45(10):2920-8. PubMed ID: 18336911
[TBL] [Abstract][Full Text] [Related]
2. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
[TBL] [Abstract][Full Text] [Related]
3. New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.
Krawczyk M; Masternak K; Zufferey M; Barras E; Reith W
Mol Cell Biol; 2005 Oct; 25(19):8607-18. PubMed ID: 16166641
[TBL] [Abstract][Full Text] [Related]
4. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency.
Durand B; Sperisen P; Emery P; Barras E; Zufferey M; Mach B; Reith W
EMBO J; 1997 Mar; 16(5):1045-55. PubMed ID: 9118943
[TBL] [Abstract][Full Text] [Related]
5. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
[TBL] [Abstract][Full Text] [Related]
6. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
Wiszniewski W; Fondaneche MC; Louise-Plence P; Prochnicka-Chalufour A; Selz F; Picard C; Le Deist F; Eliaou JF; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
[TBL] [Abstract][Full Text] [Related]
7. Three novel mutations of the CIITA gene in MHC class II-deficient patients with a severe immunodeficiency.
Dziembowska M; Fondaneche MC; Vedrenne J; Barbieri G; Wiszniewski W; Picard C; Cant AJ; Steimle V; Charron D; Alca-Loridan C; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2002 Feb; 53(10-11):821-9. PubMed ID: 11862382
[TBL] [Abstract][Full Text] [Related]
8. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells.
Nagarajan UM; Peijnenburg A; Gobin SJ; Boss JM; van den elsen PJ
J Immunol; 2000 Apr; 164(7):3666-74. PubMed ID: 10725724
[TBL] [Abstract][Full Text] [Related]
9. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.
Nekrep N; Geyer M; Jabrane-Ferrat N; Peterlin BM
Mol Cell Biol; 2001 Aug; 21(16):5566-76. PubMed ID: 11463838
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
11. Multiple interactions between BRG1 and MHC class II promoter binding proteins.
Mudhasani R; Fontes JD
Mol Immunol; 2005 Apr; 42(6):673-82. PubMed ID: 15781111
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics of the Bare lymphocyte syndrome.
Masternak K; Muhlethaler-Mottet A; Villard J; Peretti M; Reith W
Rev Immunogenet; 2000; 2(2):267-82. PubMed ID: 11258423
[TBL] [Abstract][Full Text] [Related]
13. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency.
Villard J; Lisowska-Grospierre B; van den Elsen P; Fischer A; Reith W; Mach B
N Engl J Med; 1997 Sep; 337(11):748-53. PubMed ID: 9287230
[TBL] [Abstract][Full Text] [Related]
14. Type III bare lymphocyte syndrome associated with a novel RFXAP mutation: a case report.
Gokturk B; Artac H; van Eggermond MJ; van den Elsen P; Reisli İ
Int J Immunogenet; 2012 Aug; 39(4):362-4. PubMed ID: 22390233
[TBL] [Abstract][Full Text] [Related]
15. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic control of the major histocompatibility complex class Ib gene HLA-G in trophoblast cell lines.
Holling TM; Bergevoet MW; Wierda RJ; van Eggermond MC; van den Elsen PJ
Ann N Y Acad Sci; 2009 Sep; 1173():538-44. PubMed ID: 19758196
[TBL] [Abstract][Full Text] [Related]
17. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population.
Naamane H; El Maataoui O; Ailal F; Barakat A; Bennani S; Najib J; Hassar M; Saile R; Bousfiha AA
Eur J Pediatr; 2010 Sep; 169(9):1069-74. PubMed ID: 20414676
[TBL] [Abstract][Full Text] [Related]
18. MHC class II deficiency: definition of a new complementation group.
Villard J; Mach B; Reith W
Immunobiology; 1997 Dec; 198(1-3):264-72. PubMed ID: 9442397
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex.
Nekrep N; Jabrane-Ferrat N; Peterlin BM
Mol Cell Biol; 2000 Jun; 20(12):4455-61. PubMed ID: 10825209
[TBL] [Abstract][Full Text] [Related]
20. Assembly of the RFX complex on the MHCII promoter: role of RFXAP and RFXB in relieving autoinhibition of RFX5.
Garvie CW; Boss JM
Biochim Biophys Acta; 2008 Dec; 1779(12):797-804. PubMed ID: 18723135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
